| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Canthin-6-one targets multiple cellular pathways. It is a selective ERAP1 inhibitor, directly binding ERAP1 and disrupting the Hedgehog (HH) signaling pathway. The compound also inhibits bacterial DNA gyrase, preventing DNA replication. It interferes with the transcription factors NF-κB and AP-1 at the transcriptional level, contributing to its anti-inflammatory activity. Canthin-6-one also interferes with the G2/M transition in the cell cycle.
|
|---|---|
| ln Vitro |
Canthin-6-one demonstrates potent in vitro activity as an antiproliferative agent, compromising cancer cells showing multi-drug resistance. It induces apoptosis in various human cancer cell lines, including leukemia, thyroid carcinoma, and hepatocellular carcinoma. The compound exhibits antimicrobial activity and anti-inflammatory effects through inhibition of NF-κB and AP-1. It has antifungal activity with a unique mechanism of action. Canthin-6-one shows selectivity for cancer stem cells over neuronal stem cells.
|
| ln Vivo |
In vivo activity of canthin-6-one has been demonstrated in models of inflammatory bowel disease, where it suppresses the production of proinflammatory cytokines such as IL-1β, IL-6, and TNFα from macrophages. The compound crosses the blood-brain barrier (BBB), suggesting potential for central nervous system applications. Its anticancer and anti-inflammatory activities warrant further in vivo investigation in appropriate disease models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for canthin-6-one include ERAP1 binding assays to measure its inhibitory activity (IC50 = 46.24 nM). The compound's ability to inhibit DNA gyrase can be assessed using enzymatic assays measuring DNA supercoiling or relaxation. Its effects on NF-κB and AP-1 transcription factors can be evaluated using reporter gene assays. These assays help characterize the compound's molecular targets and mechanism of action.
|
| Cell Assay |
In vitro cellular assays for canthin-6-one involve treating cancer cell lines (e.g., leukemia, thyroid carcinoma, hepatocellular carcinoma) with varying concentrations of the compound and measuring cell viability using MTT or other assays. Apoptosis is assessed using Annexin V staining or caspase activity assays. Anti-inflammatory activity is evaluated by measuring cytokine production (IL-1β, IL-6, TNFα) in activated macrophages. These assays demonstrate the compound's anticancer and anti-inflammatory activities.
|
| Animal Protocol |
In vivo animal experiments for canthin-6-one have been conducted in models of inflammatory bowel disease, where the compound suppresses proinflammatory cytokine production. The compound crosses the blood-brain barrier, suggesting potential for studies in neurological disease models. Further in vivo studies in cancer models would be valuable to evaluate its antitumor efficacy and safety profile.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for canthin-6-one indicate that it crosses the blood-brain barrier (BBB), suggesting good central nervous system penetration. Its absorption, distribution, metabolism, and excretion properties have not been extensively characterized. Further pharmacokinetic studies are needed to determine its bioavailability, half-life, and tissue distribution for potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for canthin-6-one are limited in the available literature. The compound's selectivity for cancer stem cells over neuronal stem cells suggests a favorable safety profile. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References |
[1]. O'Donnell G, Gibbons S. Antibacterial activity of two canthin-6-one alkaloids from Allium neapolitanum. Phytother Res. 2007;21(7):653-657.
|
| Additional Infomation |
Cansin-6-one is an indole alkaloid with the structure 6H-indolo[3,2,1-de][1,5]naphthidine, with a carbonyl group substituted at the 6-position. It is both a metabolite and an anti-mycobacterial drug. It is an indole alkaloid, an organic heterotetracyclic compound, and an enone. Cansin-6-one has been reported to be found in Zanthoxylum piasezkii, Zanthoxylum ovalifolium, and other organisms with relevant data.
Canthin-6-one (CAS#: 479-43-6) is an indole alkaloid from Ailanthus altissima with anticancer, antimicrobial, and anti-inflammatory activities. It is a selective ERAP1 inhibitor (IC50 = 46.24 nM) and disrupts the Hedgehog signaling pathway. The compound crosses the blood-brain barrier and induces apoptosis in various cancer cell lines. It is used in research for anticancer and anti-inflammatory applications. |
| Molecular Formula |
C14H8N2O
|
|---|---|
| Molecular Weight |
220.23
|
| Exact Mass |
220.063
|
| CAS # |
479-43-6
|
| PubChem CID |
97176
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
346.5±34.0 °C at 760 mmHg
|
| Flash Point |
163.4±25.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.764
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
378
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZERVJPYNQLONEK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H8N2O/c17-13-6-5-11-14-10(7-8-15-11)9-3-1-2-4-12(9)16(13)14/h1-8H
|
| Chemical Name |
1,6-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-3,5(16),6,8,10,12,14-heptaen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5407 mL | 22.7035 mL | 45.4071 mL | |
| 5 mM | 0.9081 mL | 4.5407 mL | 9.0814 mL | |
| 10 mM | 0.4541 mL | 2.2704 mL | 4.5407 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
